Survivin and Her2 Expressions in Different Grades of Urothelial Neoplasms of Urinary Bladder

Hedieh Moradi Tabriz ¹, Elham Nazar ¹*, Seyed Ali Ahmadi¹, Esmaiel Azimi¹, Fazeleh Majidi²

1. Department of Pathology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
2. Research and Development Center Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran

KEYWORDS
HER2, Survivin, Urothelial neoplasm

ABSTRACT

Background & Objective: Urothelial neoplasm (UN) of bladder is a potentially lethal malignancy, particularly in locally advanced or metastatic cases. Development of molecular markers such as HER2 and Survivin may provide useful information on diagnosis and prognosis in UN of bladder.

Methods: We studied the immunohistochemical (IHC) expression of HER2 and Survivin in 84 radical/partial cystectomy and transurethral resection (TUR) specimens with different histologic grades and stages. All samples were obtained from Pathology Department of Sina Hospital in Tehran, Iran from 2014 to 2018.

Results: From the total number of 84 UN samples, 10 cases (11.9%) showed papillary neoplasm of low malignant potential, 30 cases (35.7%) presented with low-grade papillary urothelial neoplasm, and 44 cases (52.4%) diagnosed as high-grade papillary urothelial neoplasm. HER2 and Survivin expressions were seen in 44 (52.4%) and 9 (10.7%) patients, respectively. Survivin expression showed a mild increase in high grade UN.

Conclusion: Our findings suggest that the IHC expression of Survivin and HER2 are not well associated with histological grades of urothelial neoplasms of bladder. This may be partly due to relatively small sample size and other factors such as patient characteristics or antibody specifications.

Main Subjects: Uropathology

Received 18 Jul 2020; Accepted 31 Aug 2020; Published Online 21 Dec 2020;

10.30699/IJP.2020.130859.2447

Corresponding Information: Elham Nazar, Department of Pathology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
Email: enazar@sina.tums.ac.ir

Copyright © 2021. This is an open-access article distributed under the terms of the Creative Commons Attribution-4.0 International License which permits Share, copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, even commercially.

Introduction

Urothelial neoplasm (UN) is the 9th most common cancer and one of the important leading causes of cancer-related death worldwide (1, 2). It is identified as the fourth and eleventh most common type of malignancy in males and females, respectively (3). UC risk factors are well known (4). At one end of the range, there are low-grade tumors which have a low developing rate and need preliminary endoscopic treatment and observation but rarely present a warning to the patient. At the other extreme, there are high-grade tumors which have a high malignancy potential associated with considerable development and high cancer mortality rates (5). Also 80% of UN cases are diagnosed as non-muscle invasive bladder cancer (NMIBC), in which up to 50% of the cases would experience recurrence and 20% would progress within 5 years (6, 7). So, UNs are categorized based on histopathologic grading and muscle invasion. The majority of them are non-invasive low-grade tumors (1). UN management is mostly based on grading and staging of the tumor, but they are not sufficient to predict the patients’ outcome (8). Standard methods are available for UN diagnosis and prognosis assessment (8). These methods are expensive and uncomfortable, so biochemical markers as alternative diagnostic methods, have been developed (9, 10). Some biochemical markers are considered to be more sensitive and specific in the target population compared with routine examination for the prognosis assessment. Also, evaluation of biochemical markers is safe, non-invasive, and easy to use; however, it is not cheap and available (8, 10). Some studies have suggested that Survivin is an apoptosis’ inhibitor protein which blocks caspase activation (6, 11, 12). In cancer cells, Survivin is expressed in the G2/M phase of the cell cycle and counteracts apoptosis induction during mitosis by interfering with the function of caspases (11). Survivin is over expressed in several human malignancies leading to tumor progression and metastasis. Likewise, in UN, Survivin expressed in tumoral tissue causes rapid progression of the disease and increased rates of recurrence (13). So Survivin, an apoptosis inhibitor protein, is a useful marker for prognostic assessments in...
invasive bladder tumors (14). Functionally, Survivin inhibits apoptosis, promotes cell proliferation, and induces/enhances angiogenesis. In transitional cell carcinoma of the urinary bladder, Survivin has been shown to be a promising biomarker for cancer diagnosis, prognosis, and prediction of possible response to intravesical or systemic therapies (15). Because of its expression in cancer but not in normal tissues, we investigated the potential suitability of Survivin immunostaining as a new molecular marker for prognosis evaluation of UN (16). Human epidermal growth factor receptor-2 (HER2) is a member of tyrosine kinase receptor family. The epidermal growth factor (EGF) family of receptor tyrosine kinases comprises four members: HER1 (EGF receptor 1 Human EGF Receptor/ErbB1), HER2 (neu/ErbB2), HER3 (ErbB3) and HER4 (ErbB4). EGF receptors are commonly active in a dimeric form and interaction between different EGF receptor pairs represents a signal diversification and amplification mechanism (1). Although it is low expressed in normal tissues, it has a significant role in the pathogenesis of some cancers (17). HER2 over-expression particularly characterizes aggressive cancer types of various origins with poor outcome (18). Only a few studies have been conducted regarding the importance of HER2 status in UN, so there is still controversy over this subject (19). Our study aims to evaluate HER2 and Survivin expressions using immunohistochemical (IHC) analysis and their association with histologic grade of UNs.

**Materials and Methods**

**Sample Selection**

A total number of 84 cases of transitional bladder tumor were selected from the pathology archive of Sina Hospital affiliated to Tehran University of Medical Sciences from 2014 to 2018. The specimens were obtained via transurethral resection (TUR) and cystectomy (radical or partial). Patients’ records were obtained via transurethral resection (TURBT). Out of 84 cases with bladder papillary neoplasm, 44 cases (52.4%) were diagnosed as high-grade papillary urothelial carcinoma, and 44 cases (52.4%) were excluded. Slides were re-assessed by an expert pathologist who was unaware of the patients’ history. After confirmation of diagnosis, appropriate blocks of each sample were selected. The specimens were classified according to the grade of tumor progression elaborated by World Health Organization (WHO)/International Society of Urological Pathology (ISUP) criteria approved in 2016 (20). Tumor staging was also performed according to the College of American Pathologists (CAP) guideline. Other assessed items included muscle invasion, perineural invasion, lymphatic invasion, blood vascular invasion, multifocality or unifocality of tumor and presence of in situ component (21).

**Immunohistochemistry Staining**

We prepared 2 mm thick paraffin blocks. Slides were coated with Poly-L-lysine and then deparaffined and rehydrated. IHC staining was performed on one representative slide per tumor which exhibited a maximum of tumoral tissue in order to detect HER2 and Survivin expression. A 1:250 dilution of primary antibody (Polyclonal rabbit anti-human C-erb B-2, Dako) was prepared according to the manufacturer’s protocol for HER2 staining. A 1:100 dilution of Survivin (clone12c4, Dako, USA-monoclonal mouse anti human) was also prepared according to the manufacturer’s protocol. Hematoxylin was used to stain the background. Breast carcinoma samples positive control was used to evaluate HER2. HER2 expression staining was graded according to Table 1 (22) (Figure 1). For Survivin, tumors which showed increased expression in more than 10% of the nuclear tumoral cells, were considered positive in our study (23, 24) (Figure 2).

**Statistical Analysis**

Statistical analysis of the results was performed using SPSS-18 software (SPSS Inc., Chicago, IL., USA). The HER2 and Survivin expressions were evaluated in general as well as correlation with tumor grade of the disease and other variables including age, sex, and muscular layer invasion. T-test and Chi-square tests were used for data analysis. All statistical tests were two-sided, and P-value<0.05 was considered significant.

**Results**

The study included 84 cases comprised of 76 males (90.5%) and 8 females (9.5%) with the average age of 62.6 years and standard deviation of 13.1 years (33-99 years). 30 cases (35.7%) underwent radical cystectomy, 5 cases (5.9%) underwent partial cystectomy, and 49 cases (58.3%) underwent transurethral resection of bladder tumors (TURBT).

Out of 84 cases, 10 cases (11.9%) showed papillary neoplasm of low malignant potential, 30 cases (35.7%) presented with low-grade papillary urothelial carcinoma, and 44 cases (52.4%) were diagnosed as high-grade papillary urothelial carcinoma. Our study included all grades of the cancer (low to high). Distribution of the cases with urothelial neoplasms according to the T-stage consists of 39 (46.4%) cases with muscle invasion (stage T2a, T2b, T3, T4a) and 45 cases (53.6%) without muscle invasion (stage Ta, T1).

Out of 84 cases with bladder papillary neoplasm, 44 cases (52.4%) \(P=0.610\) showed HER2 expression and 9 (10.7%) \(P=0.046\) cases showed Survivin expression (Table 2). HER2 expression staining degree ranges from 0 to +3 according to Table 1.
Fig. 1. Her2/neu IHC stain scoring in tumoral cells according to the Table 1: (A) score +3, (B) score +2, (C) score +1, (D) score 0.

Fig. 2. Positive Survivin IHC staining in 10% of nuclear tumoral cells.

Table 1. HER2 expression staining grade according to the positive control of breast carcinoma samples (21).

| Staining pattern                                                                 | score | HER2 overexpression assessment |
|---------------------------------------------------------------------------------|-------|-------------------------------|
| No staining is observed, or membrane staining is observed in less than 10% of tumor | 0     | Negative                       |
| A faint/barely perceptible membrane staining is detected in more than 10% of tumor cells. The cells are only stained in part of their membrane | 1+    | Negative                       |
HER2 overexpression assessment

| Staining pattern                                                                 | score | HER2 overexpression assessment |
|----------------------------------------------------------------------------------|-------|-------------------------------|
| A weak to moderate complete membrane staining is observed in more than 10% of the tumor cells | 2+    | Weakly positive                |
| A strong complete membrane staining is observed in more than 10% of the tumor     | 3+    | Strongly positive              |

**Table 2. Demographic distribution of the cases**

| Sex                  | Total case | Frequency | percent |
|----------------------|------------|-----------|---------|
| Male                 | 76         | 90.5%     |
| Female               | 8          | 9.5%      |

| Resection type        | Frequency | percent |
|-----------------------|-----------|---------|
| Radical cystectomy    | 30        | 35.7%   |
| Partial cystectomy    | 5         | 5.9%    |
| TUR                   | 49        | 58.3%   |

| Carcinoma type                              | Frequency | percent |
|---------------------------------------------|-----------|---------|
| papillary neoplasm of low-malignant potential | 10        | 11.9%   |
| low-grade papillary urothelial carcinoma     | 30        | 35.7%   |
| high-grade papillary urothelial carcinoma    | 44        | 52.4%   |

| T-stage | Frequency | percent |
|---------|-----------|---------|
| Ta      | 16        | 19.0%   |
| T1      | 29        | 34.5%   |
| T2a     | 18        | 21.4%   |
| T2b     | 8         | 9.5%    |
| T3      | 6         | 7.1%    |
| T4a     | 7         | 8.3%    |

| Muscle invasion | Frequency | percent |
|-----------------|-----------|---------|
| +               | 39        | 46.4%   |
| -               | 45        | 53.6%   |
| Perineural invasion | 13    | 45.5%   |
| Lymphatic invasion | 21    | 25%     |
| Blood vessels invasion | 13   | 45.5%   |
| Multi-centric tumor | 18   | 21.4%   |
| In situ component | 4      | 4.8%    |

| Markers         | Frequency | percent |
|-----------------|-----------|---------|
| HER2            | 44        | 52.4%   |
| Survivin        | 9         | 10.7%   |

The frequency of HER2 expression in different grades of urothelial neoplasms including papillary neoplasm of low malignant potential, low-grade papillary urothelial carcinoma and high-grade papillary urothelial carcinoma were 40%, 50%, 56.8%, respectively (Table 3), which were not statistically significant ($P=0.597$) by Chi-square analysis.
The frequency of Survivin in different grades of urothelial neoplasms including papillary neoplasm of low malignant potential, low-grade papillary urothelial carcinoma and high-grade papillary urothelial carcinoma was 10%, 0%, and 15.9%, respectively (Table 3), which indicates a mild increasing trend in Survivin expression in high grade UN ($P=0.057$) by Chi-square analysis.

The frequency of HER2 expression was 48.7% in urothelial neoplasms which showed invasion into the muscle layers and 55.6% in non-invasive cases (Table 3), which was not statistically significant ($P=0.531$) by Chi-square analysis.

Survivin expression was 12.8% in urothelial neoplasms with muscle layers invasion and 8.9% in non-invasive cases (Table 3), which was not statistically significant ($P=0.561$) by Chi-square analysis.

The frequency of HER2 and Survivin was evaluated considering variable factors such as patients’ sex, age, tumor size, perineural invasion, vascular invasion and lymph node involvement, tumor multicentricity, and presence of in situ regions. There was no statistically significant relation between the frequency of these markers and the above variables (Table 3) using T-test analysis ($P>0.500$).

| Table 3. Positive and negative HER2 and Survivin markers frequency rates. |
|-------------------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Immunohistochemistry staining                   | HER2 positive   | HER2 Negative   | P-value         | Survivin Positive | Survivin Negative | P-value         |
| 0                                               | 20 (23.8%)      |                 |                 | 2 (10%)          | 8 (80%)          |                 |
| 1                                               | 20 (23.8%)      |                 |                 | 30 (100%)        |                 |                 |
| 2                                               | 41 (48.8%)      |                 |                 | 7 (15.9%)        | 37 (84.1%)       |                 |
| 3                                               | 3 (3.6%)        |                 |                 | 8 (100%)         |                 |                 |
| Different tumor grades                          |                 | 0.269           | 0.046           |                 |                 |                 |
| Papillary neoplasm of low-malignant potential   | 4 (40%)         | 6 (60%)         | 2 (10%)         | 8 (80%)          |                 |                 |
| Low-grade papillary urothelial carcinoma        | 15 (50%)        | 15 (50%)        | 0               | 30 (100%)        |                 |                 |
| High-grade papillary urothelial carcinoma       | 25 (56.8%)      | 19 (43.3%)      | 7 (15.9%)       | 37 (84.1%)       |                 |                 |
| Gender                                          |                 | 0.662           |                 | 0.590            |                 |                 |
| Male                                            | 38 (50%)        | 38 (50%)        | 9 (11.8%)       | 67 (88.2%)       |                 |                 |
| Female                                          | 6 (75%)         | 2 (25%)         | 0               | 8 (100%)         |                 |                 |
| Muscle invasion                                 |                 | 0.662           |                 | 0.727            |                 |                 |
| +                                               | 19 (48.7%)      | 20 (51.3%)      | 5 (12.8%)       | 34 (87.2%)       |                 |                 |
| -                                               | 25 (55.6%)      | 20 (44.4%)      | 4 (8.9%)        | 41 (91.1%)       |                 |                 |
| Perineural invasion                             |                 | 0.765           |                 | 0.100            |                 |                 |
| +                                               | 6 (46.2%)       | 7 (53.8%)       | 1 (7.7%)        | 12 (92.3%)       |                 |                 |
| -                                               | 38 (53.5%)      | 33 (46.5%)      | 8 (11.3%)       | 63 (88.7%)       |                 |                 |
| Lymphatic invasion                              |                 | 0.801           |                 | 0.100            |                 |                 |
| +                                               | 10 (47.6%)      | 11 (52.4%)      | 2 (9.5%)        | 19 (90.5%)       |                 |                 |
| -                                               | 34 (54%)        | 29 (46%)        | 7 (11.1%)       | 56 (88.9%)       |                 |                 |
| Blood vessel invasion                           |                 | 0.765           |                 | 0.100            |                 |                 |
| +                                               | 6 (46.2%)       | 7 (53.8%)       | 1 (7.7%)        | 12 (92.3%)       |                 |                 |
| -                                               | 38 (53.5%)      | 33 (46.5%)      | 8 (11.3%)       | 63 (88.7%)       |                 |                 |
| Multicentricity                                 |                 | 0.109           |                 | 0.100            |                 |                 |
| +                                               | 6 (33.3%)       | 12 (66.7%)      | 2 (1.1%)        | 16 (88.9%)       |                 |                 |
Discussion

The role of HER2 in bladder cancer remains controversial (16). Increased expression of the EGF receptors, and HER2 is related to poor prognosis in most cancer studies (25). Recently, with the advent of recombinant humanized monoclonal anti-HER2 antibody (trastuzumab, Herceptin), assessment of HER2 expression has gained therapeutic significance (17). At present, targeted anti-HER2 therapies are established clinical routines for HER2 over-expressing/amplified carcinomas of the breast and stomach. Recent studies have evaluated HER2 status in urothelial neoplasms to assess the therapeutic potential of this target, demonstrate significant protein over-expression (score 2+ or 3+) or gene amplification in approximately 10% of the tumors (26). Expression of Survivin, an apoptosis inhibitor protein, is up-regulated in many tumors of epithelial origin and frequently associates with disease prognosis (27). Detection of Survivin or its associated gene signature may provide an early biomarker of aggressive tumor behavior before the appearance of tissue abnormalities (28). Several studies on UN have indicated that there may be a relationship between Survivin expression and ultimate behavior of the carcinoma, although the exact nature of this relationship is still not fully understood, because the results of some of these studies seem to be contradictory (29). There are a few conflicting reports regarding the association of Survivin expression with recurrence rates in non-muscle invasive bladder cancers (30). Also, Survivin proteins were identified as strong independent prognostic factors in patients with advanced bladder cancer (31). According to some related research, HER2 expression in metastasizing urothelial neoplasm is relatively frequent, homogeneous in each tumor component, and predicts poor prognosis (32). But some studies suggest that analyzing the HER2 status does not indicate any prognostic information in patients with UN (27). Therefore, we determined the association of Survivin and HER2 expression with clinical and pathologic characteristics in patients with different grades in UN. Our study showed high incidence rate of Survivin expression in high-grade papillary urothelial carcinoma. This result was similar to some recent studies (14, 31, 33, 34). There was no significant relation between HER2 incidence and grade of UN. For HER2 evaluation, Fluorescence in situ hybridization (FISH) might be more accurate than IHC staining and this is a possible cause of different results in some studies compared to our study (21).

Conclusion

Survivin and HER2 expressions evaluation in different histopathologic grades of urothelial neoplasms of urinary bladder suggest that the IHC expression of Survivin and HER2 are not associated with histological grade of urothelial neoplasms of bladder. This may be in part due to the relatively small sample size and other factors such as patient characteristics or antibody specifications.

Acknowledgements

The authors would like to thank statistics consultants of the Research Development Center of Sina Hospital for their technical assistance.

Conflict of interest

The authors had no conflict of interest to report.

Funding

There is no funding source.

References

1. Nedjadi T, Al-Maghrabi J, Assidi M, Dallol A, Al-Kattabi H, Chaudhary A, et al. Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques. BMC Cancer. 2016;16:653. [DOI:10.1186/s12885-016-2703-5] [PMID] [PMCID]

2. Cumberbatch MGK, Noon AP. Epidemiology, aetiology and screening of bladder cancer. Transl Androl Urol. 2019;8(1):5-11. [DOI:10.21037/tau.2018.09.11] [PMID] [PMCID]

3. Sharp JD, Hausladen DA, Maher MG, Wheeler MA, Altieri DC, Weiss RM. Bladder cancer detection with urinary survivin, an inhibitor of apoptosis. Front Biosci. 2002;7(1):e36-41. [DOI:10.2741/sharp] [PMID]

4. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6 Suppl 1):4-34. [DOI:10.1016/j.urology.2005.07.062] [PMID]

5. Tolkach Y, Stahl AF, Niehoff EM, Zhao C, Kristiansen G, Muller SC, et al. YRNA expression predicts survival in bladder cancer patients. BMC Cancer. 2017;17(1):749. [DOI:10.1186/s12885-017-3746-y] [PMID] [PMCID]
160 Survivin and HER2 in Urothelial Neoplasms

6. Tan WS, Tan WP, Tan MY, Khetrapal P, Dong L, deWinter P, et al. Novel urinary biomarkers for the detection of bladder cancer: A systematic review. Cancer Treat Rev. 2018;69:39-52. [DOI:10.1016/j.ctrv.2018.05.012] [PMID]

7. Koletas N, Koleta T, Choidas S, Anagnostopoulo K, Touloupidis S, Zarambous T, et al. Immunohistochemical Investigation of HER/AKT/mTOR Pathway and Cellular Adhesion Molecules in Urothelial Carcinomas. Patholog Res Int. 2017;2017:6794150. [DOI:10.1155/2017/6794150] [PMID] [PMCID]

8. Chou R, Gore JL, Buckley D, Fu R, Gustafson K, Griffin JC, et al. Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163(12):922-31. [DOI:10.7326/M15-0997] [PMID]

9. Jin H, Lin T, Han P, Yao Y, Zheng D, Hao J, et al. Efficacy of Raman spectroscopy in the diagnosis of bladder cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2019;88(47):e18066. [DOI:10.1097/MD.0000000000018066] [PMID] [PMCID]

10. Liang Z, Xin R, Yu Y, Wang R, Wang C, Liu X. Diagnostic value of urinary survivin as a biomarker for bladder cancer: a systematic review and meta-analysis of published studies. World J Urol. 2016;34(3):1273-81. [DOI:10.1007/s00345-018-2285-8] [PMID] [PMCID]

11. El-Hakim TFA, El-Shafie MK, Abdou AG, Azmy RM, El-Naidany SS, El-Din MOB. Value of urinary survivin as a diagnostic marker in bladder cancer. Anal Quant Cytopathol Histopathol. 2014;36(3):121-7.

12. Weikert S, Christoph F, Schrader M, Krause H, Miller K, Muller M. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer. 2005;65(9):3531-4. [DOI:10.1002/ijc.21000] [PMID]

13. Ohsawa I, Nishimura T, Kondo Y, Kimura G, Satoh M, Matsuzawa I, et al. Detection of urine survivin in 40 patients with bladder cancer. J Nippon Med Sch. 2004;71(6):379-83. [DOI:10.1272/jmms.71.379] [PMID]

14. Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol. 2008;26(1):59-65. [DOI:10.1007/s00345-007-0219-3] [PMID]

15. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altiere DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA. 2001;285(3):324-8. [DOI:10.1001/jama.285.3.324] [PMID]

16. Memon AA, Sorensen B, Melgaard P, Fokdal L, Thykjaer T, Nexø E. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br J Cancer. 2006;94(11):1703-9. [DOI:10.1038/sj.bjc.6603154] [PMID] [PMCID]

17. Tschui J, Vassella E, Bandi N, Baumgartner U, Genitsch V, Rotzer D, et al. Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer. Virchows Arch. 2015;466(6):703-10. [DOI:10.1007/s00428-015-1729-4] [PMID] [PMCID]

18. Abdelrahman AE, Rashied HE, Elkady E, Elsebai EA, El-Azomy A, Matar I. Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer. Ann Diagn Pathol. 2019;39:42-52. [DOI:10.1016/j.anadiagnost.2019.01.002] [PMID]

19. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016;70(1):106-19. [DOI:10.1016/j.euro.2016.02.028] [PMID]

20. Fitzgibbons PL, Lazar AJ, Spencer S. Introducing new College of American Pathologists reporting templates for cancer biomarkers. Arch Pathol Lab Med. 2014;138(2):157-8. [DOI:10.5858/arpa.2013-0233-EL] [PMID]

21. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18-43. [DOI:10.1200/JCO.2006.09.2775] [PMID]

22. Breyer J, Gierth M, Shalekenov S, Aziz A, Schäfer J, Burger M, et al. Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma. World J Urol. 2016;34(5):709-16. [DOI:10.1007/s00345-015-1690-5] [PMID]

23. Xi RC, Sheng YR, Chen WH, Sheng L, Gang JJ, Tong Z, et al. Expression of survivin and livin predicts early recurrence in non-muscle invasive bladder cancer. J Surg Oncol. 2013;107(5):550-4. [DOI:10.1002/jso.23272] [PMID]

24. Zhao J, Xu W, Zhang Z, Song R, Zeng S, Sun Y, et al. Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int Urol Nephrol. 2015;47(1):87-94. [DOI:10.1007/s11255-014-0866-z] [PMID]

25. Kolla SB, Seth A, Singh MK, Gupta NP, Hemal AK, Dogra PN, et al. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol. 2008;40(2):321-7. [DOI:10.1007/s11255-007-9283-x] [PMID]

26. Schultz I, Kienemey L, Witjes J, Schalken J, Willems J, Swinkels D, et al. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res. 2003;23(4):3273-32.

27. Salz W, Eisenberg D, Plescia J, Garlick DS, Weiss RM, Wu XR, et al. A survivin gene signature predicts aggressive tumor behavior. Cancer Res. 2005;65(9):3531-4. [DOI:10.1158/0008-5472.CAN-04-4284] [PMID]
28. Akhtar M, Gallagher L, Rohan S. Survivin: role in diagnosis, prognosis, and treatment of bladder cancer. Adv Anat Pathol. 2006;13(3):122-6. [DOI:10.1097:00125480-200605000-00003] [PMID]

29. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2007;109(6):1106-13. [DOI:10.1002/cncr.22521] [PMID]

30. Als AB, Dyrskjot L, von der Maase H, Koed K, Mansilla F, Toldbod HE, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res. 2007;13(15 Pt 1):4407-14. [DOI:10.1158/1078-0432.CCR-07-0109] [PMID]

31. Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalman GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol. 2011;60(2):350-7. [DOI:10.1016/j.eururo.2011.05.035] [PMID]

32. Eltze E, Wulphing C, Von Struensee D, Piechota H, Buerger H, Hertle L, Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int J Oncol. 2005;26(6):1525-31. [DOI:10.3892/ijo.26.6.1525] [PMID]

33. Ning S, Fuessel S, Kotzsch M, Kraemer K, Kappler M, Schmidt U, et al. siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol. 2004;25(4):1065-71. [DOI:10.1016/S1569-9056(04)90204-7] [PMID]

34. Lehner R, Lucia MS, Jarboe EA, Orlicky D, Shroyer AL, McGregor JA, et al. Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morphol. 2002;10(2):134-8. [DOI:10.1097/00129039-200206000-00007] [PMID]